SEARCH
Search Details
Last Updated :2025/07/05
Yoshimi Muta
Lecturer/Senior Assistant Professor
Research activity information
■ Award
- 2024
公益財団法人 鈴木万平糖尿病財団, 海外留学助成 - 2024
公益信託 九州大学医学部同窓会国際研究助成基金, 国際研究助成基金 研究助成 - Sep. 2018
日本体質医学会, 第68回体質医学会総会 若手研究奨励賞
- Liver function effects of SGLT2 inhibitor and GLP-1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study).
Daisuke Tsuriya; Kazuo Kobayashi; Kei Takeshita; Takuya Hashimoto; Moritsugu Kimura; Yoshimi Muta; Hisashi Yokomizo; Yuichi Takashi; Shunichiro Tsukamoto; Kouichi Tamura; Keizo Kanasaki; Daiji Kawanami; Masao Toyoda
Journal of diabetes investigation, 07 May 2025 - Influence of Combination Therapy with Dulaglutide or Liraglutide and SGLT2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Post-hoc Analysis of the RECAP Study.
Yoshimi Muta; Kazuo Kobayashi; Masao Toyoda; Shunichiro Tsukamoto; Daisuke Tsuriya; Yuichi Takashi; Hisashi Yokomizo; Kei Takeshita; Takuya Hashimoto; Moritsugu Kimura; Kouichi Tamura; Keizo Kanasaki; Daiji Kawanami
The Tokai journal of experimental and clinical medicine, 20 Apr. 2025, 50(1):1 - 9 - Two Cases of Tumor-induced Osteomalacia Resulting in Surgical Resection During Burosumab Therapy
Dai Nagata; Yuichi Takashi; Mayuko Yamamoto; Kyoko Toyokawa; Kensuke Makihata; Haruki Koganemaru; Saki Hideshima; Yoshimi Muta; Hisashi Yokomizo; Hironori Fukumoto; Shizuhide Nakayama; Hiroko Muta; Mikiko Aoki; Hiroshi Abe; Takuaki Yamamoto; Makoto Hamasaki; Daiji Kawanami
Internal Medicine, 2025 - Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined
sodium‐glucose cotransporter‐2 inhibitor andglucagon‐like peptide ‐1 receptor agonist treatment in patients with type 2 diabetes andchronic kidney disease
Shunichiro Tsukamoto; Kazuo Kobayashi; Masao Toyoda; Atsuhito Tone; Daiji Kawanami; Daisuke Suzuki; Daisuke Tsuriya; Hideo Machimura; Hidetoshi Shimura; Hiromichi Wakui; Hiroshi Takeda; Hisashi Yokomizo; Kei Takeshita; Keiichi Chin; Keizo Kanasaki; Masaaki Miyauchi; Masuo Saburi; Miwa Morita; Miwako Yomota; Moritsugu Kimura; Nobuo Hatori; Shinichi Nakajima; Shun Ito; Takashi Murata; Takaya Matsushita; Takayuki Furuki; Takuya Hashimoto; Tomoya Umezono; Yoshimi Muta; Yuichi Takashi; Kouichi Tamura
Diabetes, Obesity and Metabolism, 19 May 2024 - Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study
Yoshimi Muta; Kazuo Kobayashi; Masao Toyoda; Atsuhito Tone; Daisuke Suzuki; Daisuke Tsuriya; Hideo Machimura; Hidetoshi Shimura; Hiroshi Takeda; Hisashi Yokomizo; Kei Takeshita; Keiichi Chin; Keizo Kanasaki; Kouichi Tamura; Masaaki Miyauchi; Masuo Saburi; Miwa Morita; Miwako Yomota; Moritsugu Kimura; Nobuo Hatori; Shinichi Nakajima; Shun Ito; Shunichiro Tsukamoto; Takashi Murata; Takaya Matsushita; Takayuki Furuki; Takuya Hashimoto; Tomoya Umezono; Yuichi Takashi; Daiji Kawanami
Frontiers in Pharmacology, 27 Mar. 2024, 15 - Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication
Kazuo Kobayashi; Masao Toyoda; Atsuhito Tone; Daiji Kawanami; Daisuke Suzuki; Daisuke Tsuriya; Hideo Machimura; Hidetoshi Shimura; Hiroshi Takeda; Hisashi Yokomizo; Kei Takeshita; Keiichi Chin; Keizo Kanasaki; Masaaki Miyauchi; Masuo Saburi; Miwa Morita; Miwako Yomota; Moritsugu Kimura; Nobuo Hatori; Shinichi Nakajima; Shun Ito; Shunichiro Tsukamoto; Takashi Murata; Takaya Matsushita; Takayuki Furuki; Takuya Hashimoto; Tomoya Umezono; Yoshimi Muta; Yuichi Takashi; Kouichi Tamura
Diabetes and Vascular Disease Research, Nov. 2023, 20(6) - Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report.
Yuichi Takashi; Kyoko Toyokawa; Naoki Oda; Yoshimi Muta; Hisashi Yokomizo; Seiji Fukumoto; Daiji Kawanami
Frontiers in endocrinology, 2022, 13:1004624 - 1004624 - High-mobility group box 2 protein is essential for the early phase of adipogenesis.
Hidetaka Morinaga; Yoshimi Muta; Tomoko Tanaka; Makito Tanabe; Yuriko Hamaguchi; Toshihiko Yanase
Biochemical and biophysical research communications, 11 Jun. 2021, 557:97 - 103 - Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.
Daiji Kawanami; Yuichi Takashi; Yoshimi Muta; Naoki Oda; Dai Nagata; Hiroyuki Takahashi; Makito Tanabe
Frontiers in pharmacology, 2021, 12:754239 - 754239 - Selective androgen receptor modulator, S42 has anabolic and anti-catabolic effects on cultured myotubes.
Yoshimi Muta; Tomoko Tanaka; Yuriko Hamaguchi; Nobuya Hamanoue; Ryoko Motonaga; Makito Tanabe; Takashi Nomiyama; Hajime Nawata; Toshihiko Yanase
Biochemistry and biophysics reports, Mar. 2019, 17:177 - 181
- メタボ治療のゲームチェンジャー!?GIP/GLP-1受容体作動薬 臨床データからみるGIP/GLP-1受容体作動薬の多面的作用〈2〉体重減少作用
牟田芳実; 川浪大治
薬局, 2025, 76(5) - 糖尿病患者の救急医療・急性期医療 5 乳酸アシドーシス
牟田芳実; 川浪大治
月刊糖尿病, 2024, 16(1)
